Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease A Randomized Trial
Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease A Randomized Trial
复制标题
DOI：
10.1161/hypertensionaha.119.12892
复制
发表时间：
2019-08-01
期刊：
影响因子：
8.3
通讯作者：
Claassen, Jurgen A. H. R.
中科院分区：
文献类型：
--
作者：
de Jong, Daan L. K.;de Heus, Rianne A. A.;Claassen, Jurgen A. H. R.
脑血管变化，包括脑血流量（CBF）减少，发生在阿尔茨海默病发展的早期，并可能加速疾病进展。这项随机、双盲、安慰剂对照研究调查了6个月的钙拮抗剂尼伐地平治疗如何影响轻度至中度阿尔茨海默病患者的CBF。CBF测量磁共振动脉自旋标记在全脑灰质和先验定义的兴趣区域，包括海马。58名患者被随机分配（每组29名），其中两组中有22名患者没有磁共振排除标准，并且在6个月内依从药物治疗。平均年龄为72.8 ± 6.2岁，平均简易精神状态检查为20.4 ± 3.4。尼伐地平治疗降低收缩压（Delta=-11.5 [95%CI，-19.7 to -3.2] mmHg; P
Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 months. Mean age was 72.8 +/- 6.2 years, mean mini-mental state examination was 20.4 +/- 3.4. Nilvadipine treatment lowered systolic blood pressure (Delta=-11.5 [95% CI, -19.7 to -3.2] mm Hg; P